TD Cowen raises Arcutis stock price target on Zoryve momentum
TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a catalyst for short-term price appreciation.
Market read
Earnings and guidance update are primary drivers for ARQT's near-term trade.
What to watch
Potential regulatory or competitive risks for Zoryve.
Background
Arctus Biotherapeutics reported Q3 2026 results, beating revenue expectations but missing earnings, and raised its 2026 guidance.
Ticker impact
TD Cowen raised its price target to $40 and noted Q3 revenue beat and guidance increase for Arctus Biotherapeutics.
likely upward pressure as investors price in higher guidance and target.
The analyst upgrade and guidance increase are fresh, material information for a biotech with a key product.
Market effects
Positive earnings may lift other dermatology biotech peers.
US biotech sector could see modest gains.
Limited to biotech investors.
Counterpoint
Guidance may be optimistic given high spending and earnings miss.
Key entities
- companyArctus Biotherapeutics
Biotech firm developing Zoryve for vitiligo.
- analystTD Cowen
Raised price target and maintained Buy rating.

